December 30, 2015
Midatech closes deal on acquiring Zuplenz
Midatech Pharma, the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, has…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
December 29, 2015
Suven gets granted 20th patent from Europe and 8th from Macau patent
Suven Life Sciences Ltd (SUVEN) has got the grant of one product patent from Europe and one product patent from Macau corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030 and 2029.
December 29, 2015
Nectar Lifesciences appoints Additional Independet Director
Nectar Lifesciences appoints Additional Independet Director
December 22, 2015
Glenmark’s Linezolid, version of Pfizer’s Zyvox, gets nod from FDA
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Linezolid Tablets, 600 mg, the therapeutic equivalent of Zyvox Tablets, 600 mg of Pharmacia and Upjohn Company, a subsidiary of Pfizer, Inc.
December 22, 2015
FDA approves India’s Aurobindo’s generic version of Alcon’s Patanol
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% which makes the product is ready for launch.
December 18, 2015
Managerial changes for Parabolic Drugs Limited
Indian pharmaceutical company Parabolic Drugs Limited has made certain changes to its board of directors. Namely, the company announced on…
December 14, 2015
AstraZeneca in talks to buy cancer drugmaker Acerta for $5 billion – WSJ
British drugmaker AstraZeneca Plc is in advanced talks to buy privately held cancer drug developer Acerta Pharma BV for more than $5 billion (£3.3 billion).
December 14, 2015
Alvogen to market Natco’s generic Tamiflu capsules until 2017
Alvogen to market Natco’s generic Tamiflu capsules until 2017.
December 10, 2015
Rhizen and Novartis enter deal for PI3K delta gamma inhibitor
Rhizen Pharmaceuticals has entered into an exclusive, worldwide agreement with Novartis for the development and commercialization of Rhizen’s inhaled dual PI3K-delta gamma inhibitor and its closely related compound for various indications.
December 9, 2015
Bristol-Myers wraps up Cardioxyl buy. Dividend increase
Bristol-Myers Squibb Company has completed the previously announced planned acquisition of Cardioxyl Pharmaceuticals, Inc.